KV PHARMACEUTICAL SIGNS POA/VITAFLO SCANDINAVIA AB TO MARKET WOMEN'S HEALTH PRODUCTS

KV Pharmaceutical Company (NYSE: KVa/KVb) today announced that it has concluded a licensing agreement with Vitaflo Scandinavia AB for its two NDA products, Gynazole-1® (butocanzole nitrate 2% vaginal cream) for yeast infections from Candida, and Clindesse(TM) (clindamycin phosphate 2% vaginal cream) for bacterial vaginosis (BV). This latest agreement adds Sweden, Denmark, Norway, Finland and Iceland, to the list of more than 50 markets worldwide in which KV has licenses in place for the sale of Gynazole-1®, and it's the fourth international licensing announcement for the more recently introduced Clindesse(TM).

Yahoo News (http://biz.yahoo.com/prnews/050919/nym159.html?.v=18)